Mcguire Va Medical Center

Richmond, Virginia 23249

0 studies enrolling now · 57 studies all time

What they study most

Acute Kidney Injury, Acute Myocardial Infarction (AMI), Acute-On-Chronic Liver Failure, Advanced Hepatocellular Carcinoma, Ascites, Atherosclerosis, Atrial Fibrillation, Atrial Flutter, Basal Energy Expenditure, Biliary Tract Cancer, Bradycardia, Carcinoma, Hepatocellular

Studies at this site

• ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack — Recruiting now
• Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) — Running, not enrolling
• A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation — Running, not enrolling
• PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease — Completed
• Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5% — Stopped early
• Extracellular RNA Markers of Liver Disease and Cancer — Stopped early
• Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites — Completed
• Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) — Completed
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) — Completed
• A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease — Completed
• Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria — Completed
• Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy — Stopped early
• A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury — Completed
• Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma — Completed
• Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease — Completed
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis — Completed
• Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study) — Running, not enrolling
• Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1 — Completed
• Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80 — Completed
• Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis — Completed
• Safety, Tolerability and Pharmacodynamics of SYNB1020 — Stopped early
• Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS) — Status unconfirmed
• Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis — Stopped early
• Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone — Completed
• Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE) — Completed
• Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis — Completed
• Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease — Stopped early
• Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH) — Completed
• Plaque Inflammation and Dysfunctional HDL in AIM-HIGH — Completed
• Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis — Completed
• Niacin Plus Statin to Prevent Vascular Events — Stopped early
• Energy Costs of Spasticity in Spinal Cord Injury: A Pilot Investigation — Stopped early
• Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness — Completed
• Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin — Completed
• A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care — Stopped early
• Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus — Completed
• A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis — Completed
• Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects — Completed
• Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C — Completed
• Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection — Completed
• Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy — Completed
• Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C — Completed
• DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension — Completed
• Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy — Completed
• Effectiveness of Pacemaker With Closed Loop Stimulation Compared to Pacemakers With and Without Standard Rate Response — Completed
• Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men — Completed
• A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia — Completed
• SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis — Completed